Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Hematological Oncology|August 11, 2025
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All StudyPatrizia Zappasodi, Ludovica Calabretta, Virginia Valeria Ferretti, et al.Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.Cancers|September 28, 2023
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All StudyNicola Stefano Fracchiolla, Mariarita Sciumè, Cristina Papayannidis, et al.American Journal of Hematology|August 30, 2023
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO studyGiovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, et al.American Journal of Hematology|August 11, 2020
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL studyAnna Candoni, Davide Lazzarotto, Felicetto Ferrara, et al.British Journal of Haematology|November 6, 2022
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL studyMichelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, et al.Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.Haematologica|May 30, 2020
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913Sabina Chiaretti, Monica Messina, Irene Della Starza, et al.Blood Advances|March 6, 2025
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AMLGiovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, et al.Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.Pageof 7